Loading the section
The price of Arcus Biosciences, Inc. (RCUS) on October 9, 2026 is 24.41 USD, +2.43% on the day. Over 52 weeks the stock traded between 14.26 USD and 31.73 USD; the price now sits 58% of the way up that range. Over the past year the price changed by +62.19%. Market capitalization is 3.06 billion USD, rank 57 among 372 stocks of the same industry with a known capitalization.
Closing prices for 09 October 2026
Next earnings report: 27 October 2026 · Earnings calendar
Arcus Biosciences, Inc. trades on NYSE under the ticker RCUS. The company belongs to the Health care sector. The trading history on this page starts on 15 March 2018.
Over the past 52 weeks RCUS has traded between 14.26 $ and 31.74 $. As of 09 October 2026 the price stood 58.08 % of the way from the 52-week low to the high.
Over one year RCUS shares rose 62.19 %; over six months they rose 9.27 %. Volatility over 90 days is 51.18 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 13.0, above the sector median of 4.0. Price to book is 5.8, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 23.89 | 24.58 | 23.75 | 24.41 | 795,200 |
| 08 October 2026 | 24.29 | 24.38 | 22.80 | 23.83 | 2M |
| 07 October 2026 | 24.23 | 24.85 | 23.90 | 24.52 | 2M |
| 06 October 2026 | 24.96 | 24.96 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Arcus Biosciences, Inc. (RCUS) is a public company in the healthcare sector. Its common stock trade on NYSE.
Over the trailing twelve months as reported to 2026-03-31, revenue was 236.0m $, net income was -369.0m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:3928 POINT EDEN WAY, HAYWARD, CA, 94545, US
Arcus Biosciences, Inc. reported revenue of 236M $ and a net loss of 369M $ over the last four quarters. Net margin is −156.36 %. Revenue changed by +67.38 % year over year. Earnings per share are −3.17 $. Market capitalisation is 3.1B $.
RCUS has a return on equity of −70.42 %, below the sector median of −41.68 %. Return on assets is −37.01 %, below the sector median of −32.11 %. Operating margin is −168.64 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 23.96 |
| 24.28 |
| 824,800 |
| 05 October 2026 | 24.19 | 24.95 | 24.11 | 24.74 | 1M |
| 02 October 2026 | 25.48 | 25.58 | 24.09 | 24.44 | 1M |
| 01 October 2026 | 25.86 | 26.26 | 25.13 | 25.23 | 1M |
| 30 September 2026 | 26.18 | 26.35 | 25.56 | 25.83 | 1M |
| 29 September 2026 | 24.93 | 26.04 | 24.76 | 25.65 | 1M |
| 28 September 2026 | 24.85 | 25.51 | 24.35 | 25.01 | 1M |
| 25 September 2026 | 25.16 | 25.29 | 24.34 | 24.97 | 2M |
| 24 September 2026 | 26.20 | 26.49 | 24.42 | 25.06 | 2M |
| 23 September 2026 | 26.86 | 27.90 | 25.85 | 26.39 | 2M |
| 22 September 2026 | 26.34 | 27.11 | 26.04 | 26.87 | 1M |
| 21 September 2026 | 25.54 | 26.03 | 25.06 | 25.95 | 1M |
| 18 September 2026 | 25.74 | 25.74 | 25.02 | 25.24 | 3M |
| 17 September 2026 | 25.31 | 25.92 | 25.05 | 25.54 | 2M |
| 16 September 2026 | 24.79 | 25.28 | 24.18 | 24.65 | 2M |
| 15 September 2026 | 23.89 | 24.35 | 23.31 | 24.32 | 2M |
| 14 September 2026 | 24.59 | 24.99 | 24.02 | 24.07 | 2M |